SCHEMBL6948885

SCHEMBL6948885

NCCNCC1CCNCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 2/20 0.59
GNAO1 P09471 2/20 0.59
GNAI1 P63096 2/20 0.59
ANPEP P15144 1/20 0.47
ERAP2 Q6P179 1/20 0.47
PRMT5 O14744 1/20 0.44
WDR77 Q9BQA1 1/20 0.44
SAT1 P21673 1/20 0.41
ALOX15 P16050 3/20 0.41
TSHR P16473 1/20 0.41
CA12 O43570 3/20 0.38
CA6 P23280 3/20 0.38
CA7 P43166 3/20 0.38
CA9 Q16790 3/20 0.38
CA14 Q9ULX7 3/20 0.38
CA5B Q9Y2D0 3/20 0.38
MEN1 O00255 1/20 0.38
RECQL P46063 1/20 0.38
KMT2A Q03164 1/20 0.38
EPHX1 P07099 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5963013 0.86 GNAI3 (0.75) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL18575576 0.84 SAT1 (0.54) GNAI3GNAO1GNAI1SAT1ALOX15
SCHEMBL4524938 0.84
SCHEMBL21987001 0.81 GNAI3 (0.55) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL669897 0.80 GNAI3 (0.56) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL6963827 0.79 SAT1 (0.45) GNAI3GNAO1GNAI1SAT1ALOX15
SCHEMBL4527928 0.79
SCHEMBL7328368 0.79 GNAO1 (0.83) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL5645562 0.79 GNAI3 (0.53) GNAI3GNAO1GNAI1ANPEPERAP2
SCHEMBL13772115 0.78 GNAO1 (0.70) GNAI3GNAO1GNAI1ANPEPERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017158616-A1 CARBAPENEM COMPOUNDS ORCHID PHARMA LTD. (IN) 2017-09-21 WO disclosed
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2010-09-02 US disclosed
EP-1268454-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2003-01-02 EP disclosed
WO-2001074796-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, VHL, RB1 GNAI3 1926/4885GNAO1 1110/4885GNAI1 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.